14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Integration of the TGx-28.65 genomic biomarker with the flow cytometry micronucleus test to assess the genotoxicity of disperse orange and 1,2,4-benzenetriol in human TK6 cells.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In vitro gene expression signatures to predict toxicological responses can provide mechanistic context for regulatory testing. We previously developed the TGx-28.65 genomic biomarker from a database of gene expression profiles derived from human TK6 cells exposed to 28 well-known compounds. The biomarker comprises 65 genes that can classify chemicals as DNA damaging or non-DNA damaging. In this study, we applied the TGx-28.65 genomic biomarker in parallel with the in vitro micronucleus (MN) assay to determine if two chemicals of regulatory interest at Health Canada, disperse orange (DO: the orange azo dye 3-[[4-[(4-Nitrophenyl)azo]phenyl] benzylamino]propanenitrile) and 1,2,4-benzenetriol (BT: a metabolite of benzene) are genotoxic or non-genotoxic. Both chemicals caused dose-dependent declines in relative survival and increases in apoptosis. A strong significant increase in MN induction was observed for all concentrations of BT; the top two concentrations of DO also caused a statistically significant increase in MN, but these increases were <2-fold above controls. TGx-28.65 analysis classified BT as genotoxic at all three concentrations and DO as genotoxic at the mid and high concentrations. Thus, although DO only caused a small increase in MN, this response was sufficient to induce a cellular DNA damage response. Benchmark dose modeling confirmed that BT is much more potent than DO. The results strongly suggest that follow-up work is required to assess whether DO and BT are also genotoxic in vivo. This is particularly important for DO, which may require metabolic activation by bacterial gut flora to fully induce its genotoxic potential. Our previously published data and this proof of concept study suggest that the TGx-28.65 genomic biomarker has the potential to add significant value to existing approaches used to assess genotoxicity.

          Related collections

          Author and article information

          Journal
          Mutat. Res.
          Mutation research
          Elsevier BV
          1873-135X
          0027-5107
          Dec 2017
          : 806
          Affiliations
          [1 ] Environmental Health Science and Research Bureau, Health Canada, Ottawa, Ontario, K1A 0K9, Canada.
          [2 ] Integrated Laboratory Systems Inc., Research Triangle Park, NC 27709, USA.
          [3 ] Department of Biochemistry and Molecular and Cellular Biology, and Department of Oncology, Georgetown University Medical Center, Washington, District of Columbia 20057, USA.
          [4 ] Drug Safety Research and Development, Pfizer Inc., Groton, CT 06340, USA.
          [5 ] Environmental Health Science and Research Bureau, Health Canada, Ottawa, Ontario, K1A 0K9, Canada. Electronic address: carole.yauk@canada.ca.
          Article
          S0027-5107(17)30079-9
          10.1016/j.mrfmmm.2017.09.002
          29017062
          4f931525-f389-4c50-8e21-141a5e7d12a1
          History

          Gene expression microarray,Genetic toxicology,Human health risk assessment,Metabolic activation,Micronucleus,TGx-28.65 genomic biomarker,TGx-DDI genomic biomarker

          Comments

          Comment on this article